CSF2 and cardiac sarcoidosis: The “Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants with Active Cardiac Sarcoidosis (RESOLVE-Heart)” (https://clinicaltrials.gov/study/NCT05351554 (accessed on 1 February 2024)) investigates the safety profile of Namilumab targeting the granulocyte-macrophage colony stimulating factor, aiming at modifying active inflammation in CS.